Benzinga | Jul 19, 2021 06:51AM EDT

NRx Pharmaceuticals Presents Evidence ZYESAMI Helps Prevent "Cytokine Storm" In Patients With COVID-19

- Sudden Rise in Inflammatory Cytokines (IL-6) Associated with Death in COVID-19 and Other Forms of Acute Respiratory Distress Syndrome

- Data from Randomized Phase 2b/3 Trial Shows Patients Treated with ZYESAMI(tm) are Significantly Less Likely to Experience IL-6 Cytokine Rise, and Have Improved Survival and Recovery from Respiratory Failure, Compared to Patients Receiving Placebo

- Data Have Been Submitted to US Food and Drug Administration (FDA) as Part of the Emergency Use Authorization (EUA) Application for ZYESAMI(tm)

- NRx Submitting Biomarker Letter of Intent to FDA Based on Phase 2b/3 Data in Support of ZYESAMI(tm) EUA Application and Future Potential Indications